-
July 15, 2021 - Curtana Pharmaceuticals Signs Development and Manufacturing Agreement with Catalent for Brain Cancer Drug CT-179
Download news release
-
June 15, 2021 - Abstract Published in Neuro-Oncology Demonstrates Curtana Pharmaceuticals’ CT-179 Prolonged Event-free Survival in an Animal Model of Medulloblastoma
Download news release
-
October 6, 2020 - Curtana Pharmaceuticals’ CT-179 Receives Rare Pediatric Disease Designation from the U.S. FDA for the Treatment of Medulloblastoma
Download news release
-
August 22, 2017 - Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas
Download news release
-
August 15, 2017 - Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas
Download news release
-
September 7, 2016 - Curtana Pharmaceuticals Selected to Present at Inaugural University Startups Demo Day in Washington, DC
Download news release
-
June 1, 2016 - Curtana Pharmaceuticals Receives Top Honors at the 5th Annual Texas Life Science Forum
Download news release
-
Nov. 18, 2015 - Gary W. Pace Joins Curtana Pharmaceuticals Board of Directors
Download news release
-
Sept. 1, 2015 - Martin Simonetti Joins Curtana Board of Directors
Download news release
-
Oct. 1, 2014 - Curtana Pharmaceuticals Awarded NIH Small Business Technology Transfer Grant To Advance Glioblastoma Therapy
Download news release
-
Aug. 21, 2014 - Curtana Pharmaceuticals Awarded $7.6 Million Grant From The Cancer Prevention And Research Institute Of Texas
Download news release
-
Nov. 27, 2013 - Curtana Adds Industry Luminaries to Scientific Advisory Board
Download news release
-
Sept. 24, 2013 - Curtana Signs Exclusive Worldwide License Agreement
Download news release
